Recent advances in the molecular pathogenesis and targeted therapies of medullary thyroid carcinoma

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorALMEIDA, Madson Q.
dc.contributor.authorHOFF, Ana O.
dc.date.accessioned2013-07-30T17:17:43Z
dc.date.available2013-07-30T17:17:43Z
dc.date.issued2012
dc.description.abstractPurpose of review This review will focus on the recent advances in molecular pathogenesis and targeted therapies for medullary thyroid carcinoma (MTC). Unlike hereditary MTC in which rearranged during transfection (RET) mutations are the most important precipitating events, in sporadic MTC the genetic or molecular biomarkers are yet to be established. Recent findings Targeted molecular therapies that inhibit RET and other tyrosine kinase receptors involved in angiogenesis have shown great promise in the treatment of metastatic or locally advanced MTC and are under investigation. In addition, the recent findings of H-RAS mutations in 56% of RET-negative sporadic MTC and the activation of the mammalian target of rapamycin (mTOR) intracellular signaling pathway in hereditary MTC suggests that additional or alternative genetic events are important for MTC pathogenesis. Summary Recently, vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor (VEGFR) 2 and VEGFR 3, RET, and epidermal growth factor receptor (EGFR), was approved for the treatment of adults with symptomatic or progressive MTC. Significant advantages for vandetanib over placebo were seen in terms of response rate, disease control rate, and biochemical response in a phase III study. Furthermore, cabozantinib (XL184), an inhibitor of VEGFR 1 and VEGFR 2, hepatocyte growth factor receptor (MET), and RET, was associated with partial response and stable disease in 29 and 41%, respectively.
dc.description.indexMEDLINE
dc.identifier.citationCURRENT OPINION IN ONCOLOGY, v.24, n.3, p.229-234, 2012
dc.identifier.doi10.1097/CCO.0b013e328351c71a
dc.identifier.issn1040-8746
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/1330
dc.language.isoeng
dc.publisherLIPPINCOTT WILLIAMS & WILKINS
dc.relation.ispartofCurrent Opinion in Oncology
dc.rightsrestrictedAccess
dc.rights.holderCopyright LIPPINCOTT WILLIAMS & WILKINS
dc.subjectantiangiogenic agents
dc.subjectmedullary thyroid carcinoma
dc.subjectrearranged during transfection
dc.subjecttargeted therapy
dc.subject.otherret protooncogene
dc.subject.otherphase-ii
dc.subject.othercancer-cells
dc.subject.othermetastasis
dc.subject.othermutations
dc.subject.otherpathway
dc.subject.otherinhibitors
dc.subject.otherefficacy
dc.subject.othertumors
dc.subject.wosOncology
dc.titleRecent advances in the molecular pathogenesis and targeted therapies of medullary thyroid carcinoma
dc.typearticle
dc.type.categoryreview
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.citation.scopus34
hcfmusp.contributor.author-fmusphcMADSON QUEIROZ DE ALMEIDA
hcfmusp.contributor.author-fmusphcANA AMELIA FIALHO DE OLIVEIRA HOFF
hcfmusp.description.beginpage229
hcfmusp.description.endpage234
hcfmusp.description.issue3
hcfmusp.description.volume24
hcfmusp.lim.ref2012
hcfmusp.origemWOS
hcfmusp.origem.pubmed22343387
hcfmusp.origem.scopus2-s2.0-84859827825
hcfmusp.origem.wosWOS:000303220400006
hcfmusp.publisher.cityPHILADELPHIA
hcfmusp.publisher.countryUSA
hcfmusp.relation.referenceAbraham D, 2011, CLIN CANCER RES, V17, P4772, DOI 10.1158/1078-0432.CCR-11-0242
hcfmusp.relation.referenceAhmed M, 2011, EUR J ENDOCRINOL, V165, P315, DOI 10.1530/EJE-11-0129
hcfmusp.relation.referenceAlmeida MO, 2011, CANCER GENET CYTOGEN, V203, P30
hcfmusp.relation.referenceRoychowdhury S, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3003161
hcfmusp.relation.referenceBrandi ML, 2001, J CLIN ENDOCR METAB, V86, P5658, DOI 10.1210/jc.86.12.5658
hcfmusp.relation.referenceCARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579
hcfmusp.relation.referenceCarr LL, 2011, CLIN CANCER RES, V16, P5260
hcfmusp.relation.referenceCohen EEW, 2008, J CLIN ONCOL, V26, P4708, DOI 10.1200/JCO.2007.15.9566
hcfmusp.relation.referenceDONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851
hcfmusp.relation.referenceDruce MR, 2011, CLIN ENDOCRINOL OXF
hcfmusp.relation.referenceEbos JML, 2009, CANCER CELL, V15, P232, DOI 10.1016/j.ccr.2009.01.021
hcfmusp.relation.referenceElisei R, 2008, J CLIN ENDOCR METAB, V93, P682, DOI 10.1210/jc.2007-1714
hcfmusp.relation.referenceENG C, 1995, CLIN ENDOCRINOL, V43, P123, DOI 10.1111/j.1365-2265.1995.tb01903.x
hcfmusp.relation.referenceFaggiano A, 2011, J CLIN ENDOCR METAB, V95, pE32
hcfmusp.relation.referenceFrank-Raue K, 2011, HUM MUTAT, V32, P51, DOI 10.1002/humu.21385
hcfmusp.relation.referenceFugazzola L, 2008, CLIN ENDOCRINOL, V69, P418, DOI 10.1111/j.1365-2265.2008.03218.x
hcfmusp.relation.referenceHAZARD JB, 1959, J CLIN ENDOCR METAB, V19, P152
hcfmusp.relation.referenceHoff AO, 2007, HEMATOL ONCOL CLIN N, V21, P475, DOI 10.1016/j.hoc.2007.04.002
hcfmusp.relation.referenceHogan AR, 2009, J SURG RES, V156, P167, DOI 10.1016/j.jss.2009.03.098
hcfmusp.relation.referenceHong DS, 2011, J CLIN ENDOCR METAB, V96, P997, DOI 10.1210/jc.2010-1899
hcfmusp.relation.referenceIwashita T, 1996, ONCOGENE, V12, P481
hcfmusp.relation.referenceKurzrock R, 2011, J CLIN ONCOL, V29, P2660, DOI 10.1200/JCO.2010.32.4145
hcfmusp.relation.referenceLam ET, 2011, J CLIN ONCOL, V28, P2323
hcfmusp.relation.referenceLoges S, 2009, CANCER CELL, V15, P167, DOI 10.1016/j.ccr.2009.02.007
hcfmusp.relation.referenceMeijer JA, 2011, CLIN ENDOCRINOL OXF, V72, P534
hcfmusp.relation.referenceMian C, 2011, EUR J ENDOCRINOL, V164, P971, DOI 10.1530/EJE-11-0079
hcfmusp.relation.referenceModigliani E, 1998, CLIN ENDOCRINOL, V48, P265, DOI 10.1046/j.1365-2265.1998.00392.x
hcfmusp.relation.referenceMoura MM, 2011, J CLIN ENDOCR METAB, V96, pE863, DOI 10.1210/jc.2010-1921
hcfmusp.relation.referenceMULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0
hcfmusp.relation.referenceMYERS SM, 1995, ONCOGENE, V11, P2039
hcfmusp.relation.referenceNicolini V, 2011, BIOCHEM PHARMACOL, V82, P778, DOI 10.1016/j.bcp.2011.06.037
hcfmusp.relation.referencePaez-Ribes M, 2009, CANCER CELL, V15, P220, DOI 10.1016/j.ccr.2009.01.027
hcfmusp.relation.referenceRapa I, 2011, J CLIN ENDOCR METAB, V96, P2146, DOI 10.1210/jc.2010-2655
hcfmusp.relation.referenceRobinson BG, 2011, J CLIN ENDOCR METAB, V95, P2664
hcfmusp.relation.referenceRohmer V, 2011, J CLIN ENDOCR METAB, V96, pE509, DOI 10.1210/jc.2010-1234
hcfmusp.relation.referenceSantoro M, 2004, CELL MOL LIFE SCI, V61, P2954, DOI 10.1007/s00018-004-4276-8
hcfmusp.relation.referenceSchlumberger MJ, 2009, J CLIN ONCOL, V27, P3794, DOI 10.1200/JCO.2008.18.7815
hcfmusp.relation.referenceSchwartz DL, 2008, HEAD NECK-J SCI SPEC, V30, P883, DOI 10.1002/hed.20791
hcfmusp.relation.referenceSherman SI, 2011, MODERN PATHOL, V24, pS44, DOI 10.1038/modpathol.2010.165
hcfmusp.relation.referenceTakahashi M, 2001, CYTOKINE GROWTH F R, V12, P361, DOI 10.1016/S1359-6101(01)00012-0
hcfmusp.relation.referenceVerbeek HHG, 2011, J CLIN ENDOCR METAB, V96, pE991, DOI 10.1210/jc.2010-2381
hcfmusp.relation.referenceWaguespack SG, 2011, NAT REV ENDOCRINOL, V7, P596, DOI 10.1038/nrendo.2011.139
hcfmusp.relation.referenceWells Jr SA, 2011, J CLIN ONCOL, V28, P767
hcfmusp.relation.referenceWells SA, 2009, CLIN CANCER RES, V15, P7119, DOI 10.1158/1078-0432.CCR-08-2742
hcfmusp.relation.referenceWells Jr SA, 2011, J CLIN ONCOL, V30, P134, DOI [DOI 10.1200/JCO.2011.35.5040, 10.1200/JCO.2011.35.5040]
hcfmusp.relation.referenceWOLFE HJ, 1973, NEW ENGL J MED, V289, P437, DOI 10.1056/NEJM197308302890901
hcfmusp.scopus.lastupdate2024-05-17
relation.isAuthorOfPublication9f21360e-d6ed-4f8e-a23b-45738a6f1b21
relation.isAuthorOfPublication4459d441-0fc6-4861-8ab8-98e0b5e0452c
relation.isAuthorOfPublication.latestForDiscovery9f21360e-d6ed-4f8e-a23b-45738a6f1b21
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
art_ALMEIDA_Recent_advances_in_the_molecular_pathogenesis_and_targeted_2012.PDF
Tamanho:
256 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - LIM/42